Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study of a Selective ERBB2 Inhibitor, CGT4255, in Patients With Advanced Solid Tumors With ERBB2 Genetic Alterations or HER2 Overexpression

NCT07361562 is registered in ClinicalTrials.gov with Cogent Biosciences, Inc. as lead sponsor.

NCT NCT07361562
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07361562 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study of a Selective ERBB2 Inhibitor, CGT4255, in Patients With Advanced Solid Tumors With ERBB2 Genetic Alterations or HER2 Overexpression
Lead sponsor
Cogent Biosciences, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
December 30, 2025
Completion date
November 30, 2028
Enrollment
100 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, adult, erbb2 altered breast cancer, erbb2 gene amplification, her2, her2 overexpression, non-small cell lung cancer